Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boehringer Will Test How Pradaxa Stacks Up To The Competition In Real-World Study

This article was originally published in The Pink Sheet Daily

Executive Summary

Global observational study is assessing real-world experience with Pradaxa and other anticoagulants in patients with newly diagnosed atrial fibrillation and at risk of stroke. Results are due in 2020.

You may also be interested in...

Anticoagulant Market Spoiled By Choice? Cost May Be True Differentiator

A new Lancet meta-analysis suggests that while four new anticoagulants are more effective than warfarin, there is little differentiation among the products. Pressed to compare the drugs at AHA, experts were apt to highlight similarities and call for competitive pricing and head-to-head trials.

Pradaxa’s U.S. Label Updated To Cite Clinical Superiority To Warfarin In Stroke Prevention

Update of label not based on new post-NDA or post-marketing data, but on a fuller review of pivotal trial data and discussions between Boehringer Ingelheim and FDA.

Xarelto Filing Puts It Out Ahead In Venous Thromboembolism

Though other novel anticoagulants are in development for treatment and prevention of venous thromboembolism, Janssen and its partner Bayer are hoping Xarelto will be coming out ahead.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts